Clinical trial Recruiting at 1 site Observational Ages 40 and up

Assessing cardiovascular and cerebrovascular events in COPD patients using different inhalers

Official title: Multinational Database Cohort Study to Assess Adverse Cardiovascular and Cerebrovascular Outcomes in Patients With COPD Initiating a Fixed Triple Therapy Containing BDP, FF and GB Administered Via DPI Compared to pMDI

Run by Chiesi Farmaceutici S.p.A. · NCT05652439 · Data updated 2026-11-12

This study is trying to see if using a Dry Powder Inhaler is safer than a Metered Dose Inhaler for older adults with COPD by looking at heart and brain-related health issues.

Quick facts

Study typeObservational
Ages40 Years and up
SexAll
Enrollment25000 (estimated)
SponsorChiesi Farmaceutici S.p.A.
Industry-sponsored
Locations1 site (London)
StatusRecruiting
StartedDecember 2, 2022
Main results expectedMarch 2027
Study endsMarch 2027
Registry record updatedOctober 22, 2026
Trial IDNCT05652439 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are COPD patients aged 40 and older who are new users of inhaled fixed triple therapy.

Probably not a fit

Patients who have recently used any form of triple therapy or have had cardiovascular hospitalization in the past 30 days may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the incidence of adverse cardiovascular and cerebrovascular events in patients with chronic obstructive pulmonary disease (COPD) who are new users of inhaled fixed triple therapy. It compares the safety profile of the Dry Powder Inhaler (DPI) against the pressurized Metered Dose Inhaler (pMDI). Data will be collected retrospectively from various European health databases, focusing on patients aged 40 and older who have been diagnosed with COPD. The study will track outcomes from the initiation of therapy until certain predefined endpoints.

Why it matters

Potential benefit: If successful, this study could provide insights into the safety of different inhaler devices for COPD patients, potentially guiding treatment choices.

How similar studies have gone: Other studies have explored similar safety assessments in COPD treatments, but this specific comparison of DPI and pMDI is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients diagnosed with COPD
* 40 years or older
* Availability of baseline information for a minimum of 12 months before the index date
* New users of single inhaler triple therapy BDP/FF/GB via DPI or pMDI

Exclusion Criteria:

* Single or multi-inhaler triple therapy in the previous 90 days before the index date
* Prescription of BDP/FF/GP administered via pMDI or DPI or any other single inhaler triple therapy in addition to a study drug on the index date.
* Hospitalization due to cardiovascular causes in the previous 30 days before the index date.

Where it's running

  • Clinical Practice Research Datalink (CPRD)
    London, United Kingdom
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.